Australia’s medical cannabis market has adopted a California-style approach to the drug, Althea chief executive Josh Fegan has claimed, as he accused the health regulator of “falling asleep at the wheel”.

Addressing a conference of potential investors, Fegan admitted the firm’s medical division has faced “extremely challenging times” and was no longer the core focus of the group.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Join or login
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...

Join the Conversation

3 Comments

  1. For the majority of people who have never smoked or tried cannabis pastilles are a discreet, palatable, highly precise dose form.

    Think about parents administering epilepsy medicine to their child… do they have an easier time with a pill, oil, or an orange-flavored (precisely and easily dosed) CBD100 pastille? What’s the better experience for the patient (child)?

  3. Oh my God. This guy is serious? “Gummies of all things” – ever spoken to an elderly care practitioner? Didn’t think so.